Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03986580
Other study ID # CP-010
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date May 1, 2020
Est. completion date December 2024

Study information

Verified date September 2023
Source Intrinsic Therapeutics
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this prospective, single-arm, multicenter study is to assess an annular closure device when used as an adjunct to a primary lumbar limited discectomy, to limited discectomy alone.


Description:

This single-arm case series will enroll 75 patients at select US (approximately 8-10) sites. Patients that are scheduled for a single-level L4-S1 discectomy and who meet the pre-operative eligibility criteria will be considered for study participation. Patients that meet all intraoperative criteria will be enrolled into the study and treated with lumbar discectomy and additional annular closure device implantation. All enrolled subjects will be followed for at least 12 months.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 55
Est. completion date December 2024
Est. primary completion date June 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: 1. Age 18 to 75 years old and skeletally mature (male or female) 2. Subjects with posterior or posterolateral disc herniations at one level between L4 and S1 with radiographic confirmation of neural compression using MRI. [Note: Intraoperatively, only patients with an anular defect (post discectomy) between 4mm and 6mm tall and 6mm and 10mm wide shall qualify.] 3. At least six (6) weeks of failed, conservative treatment prior to surgery, including physical therapy, use of anti-inflammatory medications at maximum specified dosage and/or administration of epidural/facet injections.; 4. Minimum posterior disc height of 5mm at the index level. 5. Radiculopathy (with or without back pain) with a positive Straight Leg Raise (0 - 60 degrees) 6. Oswestry Questionnaire score of at least 40/100 at baseline. 7. VAS leg pain (one or both legs) of at least 40/100 at baseline. 8. Psychosocially, mentally and physically able to fully comply with the clinical protocol and willing to adhere to follow-up schedule and requirements. Exclusion Criteria: 1. Spondylolisthesis Grade II or higher (25% slip or greater). 2. Subject requires spinal surgery other than a discectomy (with or without laminotomy) to treat leg/back pain (scar tissue and osteophyte removal is allowed). 3. Subject has back or non-radicular leg pain of unknown etiology. 4. Prior surgery at the index lumbar vertebral level 5. Subject requiring a spine DEXA (i.e., patients with SCORE of = 6) with a T Score less than -2.0 at the index level. For patients with a herniation at L5/S1, the average T score of L1-L4 shall be used. 6. Subject has clinically compromised vertebral bodies in the lumbosacral region due to any traumatic, neoplastic, metabolic, or infectious pathology. 7. Subject has sustained pathologic fractures of the vertebra or multiple fractures of the vertebra or hip 8. Subject has scoliosis of greater than ten (10) degrees (both angular and rotational). 9. Any metabolic bone disease. 10. Subject has an active infection either systemic or local. 11. Subject has cauda equina syndrome or neurogenic bowel/bladder dysfunction. 12. Subject has severe arterial insufficiency of the legs or other peripheral vascular disease. (Screening on physical examination for patients with diminution or absence of dorsalis pedis or posterior tibialis pulses. If diminished or absent by palpation, then an arterial ultrasound is required with vascular plethysmography. If the absolute arterial pressure is below 50mm of Hg at the calf or ankle level, then the patient is to be excluded.) 13. Subject has significant peripheral neuropathy, defined as a subject with Type I or Type II diabetes or similar systemic metabolic condition causing decreased sensation in a stocking-like or non-radicular and non-dermatomal distribution in the lower extremities. 14. Subject has insulin-dependent diabetes mellitus. 15. Subject is morbidly obese (defined as a body mass index >40, or weighs more than 100 lbs over ideal body weight). 16. Subject has been diagnosed with active hepatitis, AIDS, or HIV. 17. Subject has been diagnosed with rheumatoid arthritis or other autoimmune disease. 18. Subject has a known allergy to titanium, polyethylene or polyester materials. 19. Any subject that cannot have a baseline MRI taken. 20. Subject is pregnant or interested in becoming pregnant in the next 2 years. 21. Subject has active tuberculosis or has had tuberculosis in the past three (3) years. 22. Subject has a history of active malignancy: A subject with a history of any invasive malignancy (except non-melanoma skin cancer), unless he/she has been treated with curative intent and there have been no signs or symptoms of the malignancy for at least two (2) years. 23. Subject is immunologically suppressed, received steroids >1 month over the past year. 24. Currently taking anticoagulants, other than aspirin, unless the patient can be taken off the anticoagulant for surgery. 25. Subject has a current chemical/alcohol dependency or significant psychosocial disturbance. 26. Subject has a life expectancy of less than three (3) years. 27. Subject is currently involved in active spinal litigation. 28. Subject is currently involved in another investigational study. 29. Subject is incarcerated. 30. Any contraindication for MRI (e.g. claustrophobia, contrast allergy).

Study Design


Intervention

Device:
Annular closure device
Annular closure, following limited discectomy procedure at a single LS level between L4 and S1

Locations

Country Name City State
United States Indiana Spine Group Carmel Indiana
United States North Shore University Health System Evanston Illinois
United States Baptist - Lyerly Neurosurgery Jacksonville Florida
United States Orthopaedic Institute of Western Kentucky Paducah Kentucky
United States Salt Lake Orthopaedic Clinic Salt Lake City Utah
United States UC San Diego Health System San Diego California
United States Louisiana Spine Institute Shreveport Louisiana

Sponsors (1)

Lead Sponsor Collaborator
Intrinsic Therapeutics

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Blood loss Amount of blood loss measured in ml Intra-operative
Primary Procedure time Length of surgery, measured in minutes Intra-operative
Primary Hospital stay Length of the hospital stay measured in days between hospital admission and hospital discharge Post-procedure hospital discharge day (in average between 1 and 3 days post surgery)
Primary Discharge status Evaluation of improvement in motor and sensory neurologic status Post-procedure hospital discharge day (in average between 1 and 3 days post surgery)
Primary Leg pain severity (0-100 VAS score) Change from baseline of Visual Analogue Scale score (values between 0-100), with lower values representing better outcome Baseline, 4 Weeks, 3 Months, 1 year
Primary Back pain severity (0-100 VAS score) Change from baseline of Visual Analogue Scale score (values between 0-100), with lower values representing better outcome Baseline, 4 Weeks, 3 Months, 1 year
Primary ODI Change from baseline in Oswestry Disability Index. The ODI is scored on a scale from 0% to 100%, with higher scores indicating higher levels of disability Baseline, 4 Weeks, 3 Months, 1 year
Primary EQ-5D Change from baseline in EQ-5D. The EuroQol (EQ-5D) is a generic utility measure used to characterize current health states. The subject-reported questionnaire consists of 5 domains (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each of which can take one of three responses. Possible responses include three levels of severity (no problems/some or moderate problems/extreme problems) within a particular EQ-5D dimension Baseline, 4 Weeks, 3 Months, 1 year
Primary Satisfaction with surgery procedure Patient satisfaction with surgery and treatment assessed utilizing questionnaire with Composite questionnaire with 2 questions will be administered; 1.) Indicate degree of satisfaction with the outcome and 2.) likelihood of recommending the procedure to others 1 year
Primary Neurological assessment Change from baseline in sensory (sensation response at dermatomal levels) reflex, (knee jerk, ankle jerk, response measured as "normal", "increased", "absent" and "decreased") and muscle strength measured 0-5 with "0" representing no evidence of motor strength and "5" representing full resistance Baseline, 4 Weeks, 3 Months, 1 year
Primary Adverse events Change of health status with occurrence of adverse event, reported by seriousness and relationship to the device or procedure Baseline, Intra-operative, 4 Weeks, 3 Months, 1 year
Primary Hospital readmission occurrence Change from baseline in incidence of re-admissions to hospital, post treatment Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year
Primary Symptomatic reherniation incidence Change from baseline in incidence of post-operative recurrent herniation at the index level. Recurrent herniation may be confirmed surgically, or radiographically as determined by an independent review Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year
Primary Reoperation incidence Change from baseline in incidence of post-operative reoperation at the index level Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year
Primary Return to work assessment Change from baseline in work status (ability to return to work, with or without reported restrictions) 4 Weeks, 3 Months, 1 year
Primary Opioid consumption Change from baseline for all opioid based medications (routes of administration (oral, IV, transdermal), dosing (mg/ml/tablet), duration (days)). Baseline, Intra-operative, Post-procedure hospital discharge day (in average between 1 and 3 days post surgery), 4 Weeks, 3 Months, 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05277818 - Post-marketing Clinical Follow-up of the Medical Device DIVA®
Recruiting NCT05467072 - PMCFU of an Annular Closure System
Withdrawn NCT03252691 - Incidence of Large Annular Defects in Primary Lumbar Discectomy Patients
Withdrawn NCT01622413 - Trial to Show Non-inferiority / Superiority of an Endoscopic Transforaminal Discectomy to Standard Microdiscectomy N/A
Completed NCT04329598 - Effects of Whole-Body Electromyostimulation Application in Individuals With Lumbar Disc Hernia N/A
Completed NCT04061759 - Physiotherapy in Lumbar Disc Pathologies N/A
Completed NCT04073095 - Erector Spinae Plane Block and Modified-Thoracolumbar Interfascial Plane Block Following Lumbar Spinal Surgery N/A
Active, not recruiting NCT06140862 - Ankle Spine Syndrome "RAFFET Syndrome II N/A
Active, not recruiting NCT05613179 - Brain Effect Mechanism of Lever Positioning Manipulation on LDH Analgesia Based on Multimodal MRI N/A
Completed NCT04587401 - The Effects of Anesthesia on Cerebral Perfusion in Patients With High Blood Pressure N/A
Recruiting NCT05663437 - Effectiveness of Core Stabilization Exercises With and Without Neural Mobilization Technique in Female Patients With Lumbar Radiculopathy Due to Disc Herniation - an RCT Study N/A
Recruiting NCT06076408 - Effects of SNAGS With and Without Pilates in Lumbar Disc Bulge Patients N/A
Completed NCT05999253 - Comparison of the Efficacy of Thoracolumbar Interfascial Plane Block and Erector Spina Plane Block in Lumbar Discectomy
Recruiting NCT03002207 - Repairing the Defect of Intervertebral Disc With Autologous BMSC and Gelatin Sponge After Microendoscopic Discectomy for Lumbar Disc Herniation N/A
Not yet recruiting NCT05487690 - Application of 3D Printing Guide Plate in Spinal Minimally Invasive and Interventional Surgeries N/A
Completed NCT05003726 - Non-pharmacological Treatment and Pharmacological Treatment for Non-acute Lumbar Disc Herniation N/A
Completed NCT05556538 - The Effect of Subcutaneous Fat Tissue Thickness on Lumbar Transforaminal Epidural Steroid Injection Treatment Success
Not yet recruiting NCT04083703 - Evaluation of Interbody Cage Insertion in Treatment of Lumbar Disc Prolapse N/A
Completed NCT03832036 - The Diagnostic and Prognostic Value of Two Quantitative Clinical Tests in Patients With Lumbar Disc Herniation N/A
Not yet recruiting NCT05584774 - Percutaneous Endoscopic Lumbar Discectomy Add by Annuloplasty and Nucleoplasty N/A